Journal
ACTA PHARMACEUTICA SINICA B
Volume 11, Issue 7, Pages 2031-2047Publisher
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2021.01.014
Keywords
Post-traumatic stress disorder; Cannabidiol; Hydroxypropyl-beta-cyclodextrin; Inclusion complex; Hydrogels; Brain targeting; Blood.brain barrier; Intranasal administration
Categories
Funding
- Beijing Municipal Natural Science Foundation, China [7202147, 7172072]
Ask authors/readers for more resources
The study demonstrates that CBD TSGs can effectively improve various behavioral indicators in PTSD mice, and play a role in alleviating anxiety and tension. CBD TSGs treat PTSD by reducing inflammatory factor levels and increasing the expression of the 5-HT1A receptor, with intranasal administration proving to be more efficient.
Post-traumatic stress disorder (PTSD) is a psychiatric disease that seriously affects brain function. Currently, selective serotonin reuptake inhibitors (SSRIs) are used to treat PTSD clinically but have decreased efficiency and increased side effects. In this study, nasal cannabidiol inclusion complex temperature-sensitive hydrogels (CBD TSGs) were prepared and evaluated to treat PTSD. Mice model of PTSD was established with conditional fear box. CBD TSGs could significantly improve the spontaneous behavior, exploratory spirit and alleviate tension in open field box, relieve anxiety and tension in elevated plus maze, and reduce the freezing time. Hematoxylin and eosin and c-FOS immunohistochemistry slides showed that the main injured brain areas in PTSD were the prefrontal cortex, amygdala, and hippocampus CA1. CBD TSGs could reduce the level of tumor necrosis factor-alpha caused by PTSD. Western blot analysis showed that CBD TSGs increased the expression of the 5-HT1A receptor. Intranasal administration of CBD TSGs was more efficient and had more obvious brain targeting effects than oral administration, as evidenced by the pharmacokinetics and brain tissue distribution of CBD TSGs. Overall, nasal CBD TSGs are safe and effective and have controlled release. There are a novel promising option for the clinical treatment of PTSD. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available